MOLECULAR BIOLOGICAL FACTORS OF PROGNOSIS AND EFFICIENCY OF MEDICAL TREATMENT FOR DISSEMINATED RENAL CELL CARCINOMA

• Main Authors: D. A. Nosov, E. S. Yakovleva, D. A. Atayeva, L. N. Lyubchenko, S. A. Tyulyandin
• Format: Article
• Language: Russian
• Published: ABV-press 2014-08-01
• Series: Onkourologiâ
• Subjects: renal cell carcinoma; target therapy; vhl gene mutation; hypoxia-induced factor; vascular endothelial growth factor; biomarkers
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/328
• ISSN: 1726-9776; 1996-1812

The substantial improvement of treatment results in patients with disseminated forms of renal cell carcinoma (RCC) is associated with the active clinical application of target drugs that affect the molecular genetic mechanisms underlying the development of this disease. Inactivation of the VHL gene and/or the disorders related to other elements of the signaling pathway regulating the processes of proliferation and neoangionesis in tumor tissue (mammalian target of rapamycin; hypoxia-induced factor; vascular endothelial growth factor and its receptor; platelet-derived growth factor receptor; and carboanhydrase IX) are considered to be one of the early and key events in carcinogenesis in clear cell RCC. However, there is presently no consensus of opinion as the prognostic value of these disorders and their impact on the efficiency of drug therapy. The results of the clinical trials assessing potential molecular biological markers are discordant. This is attributable both to the dissimilar clinical characteristics of patients and different methodological approaches to evaluating these or those molecular impairments. There are also other alternative signaling pathways and mechanisms responsible for the formation of primary or secondary drug resistance when target agents are administered. Thus, the quest of potential biomarkers remains an urgent problem as before. This paper analyzes the results of the currently available clinical studies of the role of various biological markers in predicting the efficiency of the present-day medicinal approaches to treating patients with RCC.